TG Therapeutics (TGTX) shares jumped after the company raised its full-year guidance, citing strong demand for its multiple sclerosis drug, Briumvi. It now expects US Briumvi revenue of about $585 million, up from $570 - $575 million. Total 2025 revenue is projected at $600 million after Q3 sales beat estimates.